This study will evaluate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of patupilone combined with carboplatin in adult patients with advanced solid tumors who progressed despite standard therapy or for whom no standard therapy exists or who might benefit from treatment with carboplatin

Inclusion criteria:

• Histologically or cytologically confirmed advanced solid tumors who have progressed despite standard therapy, or for whom no standard therapy exists, or who might benefit from treatment with carboplatin
• A minimum of 4 weeks since the last treatment with chemotherapy
• WHO Performance Status 0 (able to carry out all normal activity without restriction) or 1 (restricted in physically strenuous activity but ambulatory and able to carry out work)
• Age ≥ 18
• Adequate hematological parameters
• No major impairment of renal or hepatic function
• Written informed consent obtained

Exclusion criteria:

• Major surgery less than 4 weeks prior to study entry and/or not fully recovered from surgery
• Chemotherapy or investigational compound less than 4 weeks prior to study entry, or planned while participating in the study
• Prior administration of an epothilone
• Hypersensitivity to carboplatin. Patients resistant to carboplatin are not recommended to enter the trial
• Radiotherapy (RT) less than 4 weeks prior to study entry (except for palliative therapy of distant metastases), or planned RT while participating in the study
• Diarrhea within 7 days prior to start of treatment. Unresolved bowel obstruction
• Peripheral neuropathy > Grade 1 (mild)
• Symptomatic brain metastases
• Colostomy

Other protocol-defined inclusion/exclusion criteria may apply